ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current standards of clinical practice recommend systemic chemotherapy but no surgical approach for Stage IV pancreatic ductal adenocarcinoma (PDAC), with expected overall median survival between 3 and 6 months. In the last 20 years, a subset of patients with a limited number of metastases to just one or two organs (liver and/or lungs) and a less aggressive biology and growth ability have been identified and defined as "oligometastases" (OM). The continuous improvement in systemic therapy with the arrival of the multiagent FOLFIRINOX and gemcitabine + nab-paclitaxel and the refinements and advances in surgical techniques have shifted the focus from technical resectability to biological treatment for patients with OM from PDAC. In this review we evaluate the existing evidence for metastasectomy in the liver, lungs, interaortocaval lymph nodes and peritoneum, assessing the potential indications for surgery and contributing with some general rules that can be followed.
Indexed as
Identifiers
40936060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.